With regards to MM treatment response evaluation, PET/CT also has practical value: 34 MM patients with similar M protein levels showed no differences in the dynamic radiological examination, 18F-FDG uptake showed its priority in detecting minimal tumor residual changes in continued treatment. The gene discussed is MYOM2; the disease is Miyoshi myopathy.